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Structural Basis for Mutant RXRA-Mediated
Hyperactivity of PPARs in Bladder Cancer
Chiraag Kapadia
Mentor: Vivek Arora
Understanding the structural mechanism by which an oncogenic point mutation
promotes aberrant activity is prerequisite to rational drug design. Recent genomic
characterization of bladder tumors has suggested several oncogenes relied upon for
tumor development and thus ideal for targeted inhibition. The nuclear receptor RXRA
contains a hotspot mutation and posits one such candidate oncogene. Growth assays
performed by our group demonstrated mutant RXRA drives proliferation in a bladder
urothelial organoid model, confirming the recurrent mutation’s oncogenic potential.
RXRA activates transcription as a homodimer or obligate heterodimer with sixteen
other nuclear receptors. The hotspot mutation is located at the heterodimerization
interface and contacts binding partners. Co-overexpression of RXRA with known
heterodimerization partners revealed mutant-mediated hyperactivity occurred solely
when in complex with the PPAR class of nuclear receptors, suggesting mutant RXRA is
oncogenic in a narrow range of structural contexts. Based on this structural specificity,
I speculate the RXRA/PPAR complex represents a targetable oncogenic dyad.
To define the mechanism of mutant RXRA-mediated hyperactivation of PPARG,
the PPARG ligand-binding pocket and transactivation helix (responsible for
transcriptional machinery recruitment) were mutated. Hyperactivity occurred
independent of ligand binding but relied on the PPARG transactivation helix,
suggesting an allosteric relay induces PPARG into an active conformation. To identify
the residues comprising the allosteric relay, long-timescale molecular simulations and
subsequent Markov state modeling of RXRA/PPARG were performed. Predicted
metastable states for the mutant heterodimer illustrate the PPARG transactivation helix
to predominantly adopt conformations similar to the agonist-bound crystal structure,
in contrast to conformations adopted by the wild-type dimer. The PPARG terminal
tyrosine on the mutant heterodimer occupied a distinct region in space compared to the
wild-type heterodimer, suggesting a functional relevance for this residue. Elimination
of the PPARG terminal tyrosine prevented mutant-mediated hyperactivity. These
insights will guide future chemistry efforts to inhibit.
